The Babak Lab shared a post on LinkedIn:
“Clinical Mondays: Elinzanetant Eases Hot Flashes in Breast Cancer Endocrine Therapy
A phase III trial published in NEJM (June 2025) reports that elinzanetant, a nonhormonal NK-1/NK-3 antagonist, significantly reduces vasomotor symptoms in women on endocrine therapy for hormone receptor–positive breast cancer.
Study Focus:
Assess the safety and efficacy of once-daily elinzanetant (120 mg) vs placebo in reducing moderate-to-severe hot flashes during 52 weeks of endocrine therapy.
Experimental Highlights:
- Randomized, double-blind, placebo-controlled OASIS‑4 with 474 women aged 18–70
- Elinzanetant arm: 316 participants; placebo then crossover: 158
- Baseline average: 11.4 moderate-to-severe vasomotor episodes/day
- Reduction at Week 4: −6.5 vs −3.0 episodes (p < 0.001)
- Reduction at Week 12: −7.8 vs −4.2 (p < 0.001)
- ≥50% symptom reduction in 74.3% vs 35.8% at 12 weeks
Key Findings:
- Major reduction in hot flash frequency
- Significant improvement in sleep and quality of life
- Well-tolerated; most AEs were mild (headache, fatigue, somnolence)
- Serious AEs rare (2.5% vs 0.6%), liver enzyme changes reversible
Conclusion:
Elinzanetant offers a promising nonhormonal option to manage vasomotor symptoms caused by endocrine therapy, potentially improving adherence and quality of life for breast cancer survivors.”
Title: Elinzanetant Eases Hot Flashes in Breast Cancer Endocrine Therapy
Authors: Fatima Cardoso, Susanne Parke, Donal J. Brennan, Paula Briggs, Gilbert Donders, Nick Panay, F.R.C.O.G., Nazanin Haseli-Mashhadi, Michael Block, Cecilia Caetano, Maja Francuski, Claudia Haberland, Kaisa Laapas, Christian Seitz and Lineke Zuurman
Read the Full Article.
More posts featuring The Babak Lab on OncoDaily.